Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott W Lowe

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Cancer Cell|September 8, 2023
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1Beiping Miao, Zhaoqing Hu, Riccardo Mezzadra, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Nature Biotechnology|September 11, 2010
Towards patient-based cancer therapeutics, Stuart L Schreiber, Alykhan F Shamji, et al.
Cancer Cell|June 20, 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic CancerLuisa F Escobar-Hoyos, Alex Penson, Ram Kannan, et al.
Nature Medicine|October 9, 2019
A rectal cancer organoid platform to study individual responses to chemoradiationKaruna Ganesh, Chao Wu, Kevin P O'Rourke, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Nature Genetics|September 10, 2013
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemiaSohela Shah, Kasmintan A Schrader, Esmé Waanders, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Nature|November 12, 2024
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Cancer Cell|September 8, 2023
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1Beiping Miao, Zhaoqing Hu, Riccardo Mezzadra, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Nature Biotechnology|September 11, 2010
Towards patient-based cancer therapeutics, Stuart L Schreiber, Alykhan F Shamji, et al.
Cancer Cell|June 20, 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic CancerLuisa F Escobar-Hoyos, Alex Penson, Ram Kannan, et al.
Nature Medicine|October 9, 2019
A rectal cancer organoid platform to study individual responses to chemoradiationKaruna Ganesh, Chao Wu, Kevin P O'Rourke, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Nature Genetics|September 10, 2013
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemiaSohela Shah, Kasmintan A Schrader, Esmé Waanders, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Nature|November 12, 2024
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 33